Our studies suggest that ligands that lead to stronger biased interaction of the α2AR subtypes with β-arrestins over spinophilin would be more beneficial for hypertension treatment than traditional ligands that can enhance binding of both proteins to the receptor. The gene discussed is PPP1R9B; the disease is Hypertension.